Literature DB >> 26632435

Targeting Tumors with Small Molecule Peptides.

Andrew G Cheetham, Daniel Keith, Pengcheng Zhang, Ran Lin, Hao Su, Honggang Cui1.   

Abstract

Chemotherapeutic treatment of cancers is a challenging endeavor, hindered by poor selectivity towards tumorous tissues over healthy ones. Preferentially delivering a given drug to tumor sites necessitates the use of targeting elements, of which there are a wide range in development. In this Review, we highlight recent examples of peptide-based targeting ligands that have been exploited to selectively deliver a chemotherapeutic payload to specific tumor-associated sites such as the vasculature, lymphatics, or cell surface. The advantages and limitations of such approaches will be discussed with a view to potential future development. Additionally, we will also examine how peptide-based ligands can be used diagnostically in the detection and characterization of cancers through their incorporation into imaging agents.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26632435      PMCID: PMC8848301          DOI: 10.2174/1568009616666151130214646

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  248 in total

1.  Surface immunoglobulin on B lymphocytes as a potential target for specific peptide ligands in chronic lymphocytic leukaemia.

Authors:  L Buhl; P B Szecsi; G G Gisselø; C Schafer-Nielsen
Journal:  Br J Haematol       Date:  2002-03       Impact factor: 6.998

Review 2.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

3.  Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand.

Authors:  Youngsoo Kim; Antonietta M Lillo; Sebastian C J Steiniger; Ying Liu; Carlo Ballatore; Andrea Anichini; Roberta Mortarini; Gunnar F Kaufmann; Bin Zhou; Brunhilde Felding-Habermann; Kim D Janda
Journal:  Biochemistry       Date:  2006-08-08       Impact factor: 3.162

Review 4.  RGD and other recognition sequences for integrins.

Authors:  E Ruoslahti
Journal:  Annu Rev Cell Dev Biol       Date:  1996       Impact factor: 13.827

5.  Targeting of hepatoma cell and suppression of tumor growth by a novel 12mer peptide fused to superantigen TSST-1.

Authors:  Yong-Qiang Jiang; Hai-Rong Wang; Han-Ping Li; Huai-Jie Hao; Yu-Ling Zheng; Jun Gu
Journal:  Mol Med       Date:  2006 Apr-Jun       Impact factor: 6.354

6.  Targeting the prostate for destruction through a vascular address.

Authors:  Wadih Arap; Wolfgang Haedicke; Michele Bernasconi; Renate Kain; Daniel Rajotte; Stanislaw Krajewski; H Michael Ellerby; Dale E Bredesen; Renata Pasqualini; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

Review 7.  New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.

Authors:  A V Schally; K Szepeshazi; A Nagy; A M Comaru-Schally; G Halmos
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

8.  Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2.

Authors:  A Régina; M Demeule; C Ché; I Lavallée; J Poirier; R Gabathuler; R Béliveau; J-P Castaigne
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

9.  N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer.

Authors:  Ronnie C Mease; Crystal L Dusich; Catherine A Foss; Hayden T Ravert; Robert F Dannals; Jurgen Seidel; Andrew Prideaux; James J Fox; George Sgouros; Alan P Kozikowski; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

Review 10.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

View more
  7 in total

1.  Molecular design and synthesis of self-assembling camptothecin drug amphiphiles.

Authors:  Andrew G Cheetham; Yi-An Lin; Ran Lin; Honggang Cui
Journal:  Acta Pharmacol Sin       Date:  2017-03-06       Impact factor: 6.150

2.  Anticancer effects of β-elemene with hyperthermia in lung cancer cells.

Authors:  Zhibing Wu; Ting Wang; Yanmei Zhang; Zhishuang Zheng; Shuhuan Yu; Saisai Jing; Sumei Chen; Hao Jiang; Shenglin Ma
Journal:  Exp Ther Med       Date:  2017-04-18       Impact factor: 2.447

Review 3.  Nanotherapeutic systems for local treatment of brain tumors.

Authors:  Rami Walid Chakroun; Pengcheng Zhang; Ran Lin; Paula Schiapparelli; Alfredo Quinones-Hinojosa; Honggang Cui
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-05-24

4.  Regulating the Rate of Molecular Self-Assembly for Targeting Cancer Cells.

Authors:  Jie Zhou; Xuewen Du; Bing Xu
Journal:  Angew Chem Int Ed Engl       Date:  2016-04-08       Impact factor: 15.336

5.  Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy.

Authors:  Marek T Wlodarczyk; Sylwia A Dragulska; Olga Camacho-Vanegas; Peter R Dottino; Andrzej A Jarzęcki; John A Martignetti; Aneta J Mieszawska
Journal:  ACS Biomater Sci Eng       Date:  2018-01-09

Review 6.  Self-assembling prodrugs.

Authors:  Andrew G Cheetham; Rami W Chakroun; Wang Ma; Honggang Cui
Journal:  Chem Soc Rev       Date:  2017-10-30       Impact factor: 54.564

Review 7.  Tumor-targeting peptides from combinatorial libraries.

Authors:  Ruiwu Liu; Xiaocen Li; Wenwu Xiao; Kit S Lam
Journal:  Adv Drug Deliv Rev       Date:  2016-05-19       Impact factor: 15.470

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.